# Sera Prognostics, Inc > Clarifo company profile — qualitative business description generated from > the company's filings. Financial statements, charts and ratios are > available on Clarifo (https://www.clarifo.com/fi/companies/Sera Prognostics, Inc). ## Overview Sera Prognostics, Inc. is a U.S.-based life sciences company focused on maternal health diagnostics. Its core product is the PreTRM test, a proteomic blood test designed to assess the risk of preterm birth, with additional pipeline tests and related services under development. ## Products & services • PreTRM test for preterm birth risk assessment • Proteomic clinical testing services • Specimen collection and shipping support • Pipeline maternal-health diagnostic tests • Evidence generation and clinical study support - **PreTRM diagnostic testing** (90%) — Blood-based proteomic testing used to assess preterm birth risk in pregnant patients. - **Pipeline diagnostic products** (5%) — Additional maternal-health and related tests under development for future commercialization. - **Clinical and specimen services** (5%) — Supporting services tied to test ordering, specimen collection, shipping, and processing. - PreTRM test for preterm birth risk assessment - Proteomic clinical testing services - Specimen collection and shipping support - Pipeline maternal-health diagnostic tests - Evidence generation and clinical study support ## Customers Sera sells primarily to health plans, payers, and health systems that can authorize or reimburse use of the PreTRM test. The test is ultimately used in the care pathway for pregnant patients, so adoption depends on physicians, clinicians, and payer coverage decisions. The company also relies on a limited number of direct customers, making customer concentration an important feature of the business model. - **Payers and health plans** (primary) — Buy access to PreTRM to support coverage decisions and population health management. - **Health systems and provider organizations** (primary) — Order the test for eligible patients and integrate it into obstetric workflows. - **Direct commercial customers** (primary) — Large customers such as Elevance Health that can account for a significant share of revenue. - **Clinicians and maternal-fetal care teams** (secondary) — Use test results to guide monitoring and intervention decisions. - Health plans and payers that decide coverage and reimbursement - Health systems that order tests for patient populations - Clinicians and physicians who use the test in care pathways - Pregnant patients as the end beneficiaries of the test - Direct commercial customers that can represent concentrated revenue ## Geography Sera Prognostics is headquartered in the United States and operates as a U.S. clinical diagnostics company. Its testing, commercialization, and regulatory activities are centered in the U.S., with potential expansion into foreign jurisdictions as the company seeks broader utilization of PreTRM. Geography matters because laboratory licensing, payer adoption, and clinical practice patterns can differ by state and country. - Headquartered and primarily operated in the United States - Clinical testing and commercialization are centered on the U.S. market - State-level laboratory licensing can affect where tests can be offered - Foreign expansion is possible but depends on local licensure rules - U.S. payer and provider adoption drive near-term market access ## Strategy The company’s strategy is to expand adoption of the PreTRM test through payer engagement, clinical evidence, and broader commercialization capabilities. It also seeks partnerships and other strategic options for PreTRM and future product candidates while building a pipeline beyond its initial test. Evidence generation, including published study data, is central to supporting market acceptance and reimbursement. - **Commercialize PreTRM through payer and provider adoption** (short-term) — Revenue depends on converting clinical evidence into routine test ordering and reimbursement. - **Strengthen evidence generation** (medium-term) — Clinical data supports market acceptance, guideline inclusion, and payer coverage. - **Build a broader product pipeline** (medium-term) — Future growth depends on more than one diagnostic product. - Expand PreTRM adoption through payer and health-system contracts - Use clinical evidence to support reimbursement and clinical guidelines - Build sales, marketing, and customer support capabilities - Pursue partnerships and strategic options for PreTRM and pipeline tests - Develop additional maternal-health diagnostics beyond the initial test ## Risks Sera is exposed to commercialization risk because its revenue depends heavily on adoption of a single core test and a small number of customers. It also faces clinical, regulatory, operational, and funding risks typical of an early-stage diagnostics company, including laboratory uptime, specimen logistics, and the need to raise capital to support development and commercialization. - **Dependence on PreTRM adoption** [high] — Substantially all near-term revenue is expected to come from one test, so weak market acceptance would directly reduce sales. - **Customer concentration** [high] — A limited number of direct customers, including Elevance Health, may account for a significant share of revenue and cash flow. - **Commercial execution risk** [medium] — The company has limited sales and marketing experience and must build specialized commercialization capabilities. - **Laboratory and specimen logistics disruption** [high] — Testing depends on a CLIA-certified lab plus third-party specimen collection and courier services. - **Funding and liquidity pressure** [high] — The company expects continued operating losses and may need additional capital to fund commercialization and R&D. - **Competitive and clinical adoption risk** [medium] — Competing diagnostics or unfavorable clinical evidence could limit adoption by providers and payers. - Revenue concentration in PreTRM creates product dependence risk - Customer concentration increases exposure to contract loss - Commercialization may fail if sales and marketing execution is weak - CLIA lab disruption could halt testing operations - Capital needs may exceed available funding if losses continue ## Accounting The most important accounting issue is revenue recognition tied to diagnostic test ordering, payer contracts, and customer mix, which can create timing differences between commercial activity and reported revenue. Investors should also watch estimates around stock-based compensation, lease accounting, and any impairment or valuation judgments tied to intangible assets, because the company is still building its commercial platform and may have limited operating history. - **Revenue recognition for diagnostic testing** — Can create timing differences between commercial traction and recognized revenue - **Quarterly volatility** — Makes trend analysis and comparability more difficult - **Stock-based compensation** — Can materially influence reported losses - **Impairment and valuation estimates** — Could lead to non-cash charges if assumptions weaken - Revenue timing depends on test orders and payer/customer arrangements - Quarterly results may fluctuate with contract timing and adoption patterns - Stock-based compensation can materially affect operating expenses - Lease accounting affects reported operating costs and liabilities - Impairment and valuation judgments may affect intangible assets --- *Last updated: 2026-09-24T11:53:10.847549+00:00*